Unlike PD-1/PD-L1 inhibitors, the using of CTLA-4 inhibitors would like to relieve the inhibitory effect of regulatory T cells (Treg) in the tumor microenvironment, enhancing the body’s tumor immunity to eliminate tumor cells in the body. The gene discussed is PDCD1; the disease is neoplasm.